review
Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
Claudia Cosentinoa, Ilaria Dicembrinia, Besmir Nreua, Edoardo Mannuccia, Matteo Monamia b✉
- aDiabetology, Careggi Hospital and University of Florence, Italy
- bDiabetology, Careggi Hospital and University of Florence, Italy. Electronic address: matteo.monami@unifi.it
- ✉Corresponding author
Looking for the full paper…
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased serum uric acid in type 2 diabetes. Hyperuricemia is associated with an increased risk of nephrolithiasis. The present meta-analysis, performed on trials with duration ≥52 weeks in comparison with placebo or active comparators, suggests no effects of SGLT-2i on the risk of nephrolithiasis.
TL;DRThe present meta-analysis, performed on trials with duration ≥52 weeks in comparison with placebo or active comparators, suggests no effects of SGLT-2i on the risk of nephrolithiasis. (Semantic Scholar)